A report of the Lisbon conference on the care of the kidney transplant recipient

Transplantation

Volumn 83, Issue 8 SUPPL., 2007, Pages

  Abbud Filho, Mario ^a   Adams, Patricia L ^b   Alberú, Josefina ^c   Cardella, Carl ^d   Chapman, Jeremy ^e   Cochat, Pierre ^f   Cosio, Fernando ^g   Danovitch, Gabriel ^h   Davis, Connie ⁱ   Gaston, Robert S ^j   Humar, Atul ^d   Hunsicker, Lawrence G ^k   Josephson, Michelle A ^l   Kasiske, Bertram ^m   Kirste, Günter ⁿ   Leichtman, Alan ^o   Munn, Stephen ^p   Obrador, Gregorio T ^q   Tibell, Annika ^r   Wadström, Jonas ^s   Zeier, Martin ^t   Delmonico, Francis L ^u,v   more..

^a Instituto de Urologia e Nefrologia and Medical School FAMERP   (Brazil)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSITY OF TORONTO   (Canada)

^e WESTMEAD HOSPITAL   (Australia)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF IOWA HEALTH CARE   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁿ Deutsche Stiftung Organ Transplantation ^*  (Germany)

^o UNIVERSITY OF MICHIGAN   (United States)

^p AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^q UNIVERSIDAD PANAMERICANA   (Mexico)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^t UNIVERSITY OF HEIDELBERG   (Germany)

^u MASSACHUSETTS GENERAL HOSPITAL   (United States)

^v NATIONAL KIDNEY FOUNDATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHICKENPOX VACCINE; CYANOCOBALAMIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHTHERIA TETANUS VACCINE; DIURETIC AGENT; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH HORMONE; RUBELLA VACCINE;

ANEMIA; BK VIRUS; BLOOD PRESSURE REGULATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTRACEPTION; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DYSLIPIDEMIA; FEMALE FERTILITY; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; INFECTION PREVENTION; INFECTION RISK; INTRACRANIAL PRESSURE; IRON THERAPY; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY FUNCTION TEST; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIBIDO; LIVING DONOR; MALE FERTILITY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT SELECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE EDEMA; PRACTICE GUIDELINE; PREGNANCY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

ANEMIA; BONE DISEASES; CADAVER; HUMANS; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIVING DONORS; POLYCYTHEMIA; PORTUGAL; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; TISSUE DONORS; WAITING LISTS;

EID: 34247480971     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000260765.41275.e2     Document Type: Conference Paper

References (214)

1. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1.
2. Kasiske BL, Chakkera H, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
3. Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084.
4. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 2004; 66: 441.
5. Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46: 529.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 1662.
7. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
8. Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol 2006; 17: 900.
9. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795.
10. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
11. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: Morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596.
12. Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: A common condition with poor prognostic implications. Am J Kidney Dis 2005; 46: 720.
13. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
14. Rigatto C, Foley R, Jeffery J, et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462.
15. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998; 30: 777.
16. Sung RS, Althoen M, Howell TA, Merion RM. Peripheral vascular occlusive disease in renal transplant recipients: Risk factors and impact on kidney allograft survival. Transplantation 2000; 70: 1049.
17. Aakhus S, Dahl K, Widerøe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
18. Matas AJ, Kasiske B, Miller L. Proposed guidelines for re-evaluation of patients on the waiting list for renal cadaver transplantation. Transplantation 2002; 73: 811.
19. Gaston RS, Danovitch GM, Adams PL, et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775.
20. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349.
21. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 331: 313.
22. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257: 399.
23. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-290.
24. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 7 (4 Suppl): 13.
25. American Diabetes Association (ADA).: Standards of medical care in diabetes-2006. Diabetes Care 2006; 29: S4.
26. Cosio FG, Kudva Y, van dV, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
27. Ducloux D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: A prospective study. Transplantation 2005; 79: 438.
28. Cosio FG, Falkenhain ME, Pesavento TE, et al. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant 1999; 13: 336.
29. U.S. Preventative Services Task Force: Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002; 136: 157.
30. Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum on the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation 2005; 79: S53.
31. Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35: 1513.
32. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004; 4(S10): 10.
33. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2002; 2(Suppl 1): 5.
34. Tugwell BD, Patel PR, Williams IT, et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005; 143: 648.
35. Kumar D, Humar A. Emerging viral infections in transplant recipients. Curr Opin Infect Dis 2005; 18: 337.
36. Kauffman HM, McBride MA, Cherikh WS, et al. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74: 358.
37. Delmonico FL, Reese JC. Organ donor issues for the intensive care physician. J Intensive Care Med 1998; 13: 269.
38. Halon A, Patrzalek D, Rabczynski J. Critical overview of the current status of organ donors with primary central nervous system tumors. Ann Transplant 2002; 7(1): 6.
39. Kauffman HM, McBride MA, Cherikh WS, et al. Transplant tumor registry: Donors with central nervous system tumors. Transplantation 2002; 73: 579.
40. Buell JF, Gross T, Alloway RR, et al. Central nervous system tumors in donors: Misdiagnosis carries a high morbidity and mortality. Transplant Proc 2005; 37: 583.
41. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: Donors with a history of cancer. Transplantation 2000; 70: 1747.
42. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004; 4(S10): 72.
43. Mycobacterium tuberculosis. Am J Transplant 2004; 4(Suppl 10): 37.
44. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17 (Suppl 4): 39.
45. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004; 4(S10): 160.
46. Neu AM, Fivush BA. Recommended immunization practices for pediatric renal transplant recipients. Pediatr Transplant 1998; 2: 263.
47. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
48. Cytomegalovirus. Am J Transplant 2004; 4(s10): 51.
49. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
50. Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004; 4(s10): 135.
51. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17 (Suppl 4): 1.
52. Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis 2001; 33: S53.
53. Natov SN, Pereira BJ. Management of hepatitis C infection in renal transplant recipients. Am J Transplant 2002; 2: 483.
54. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427.
55. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704.
56. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092.
57. Kamar N, Ribes D, Izopet J, Rostaing L. Treatment of hepatitis c virus infection (HCV) after renal transplantation: Implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation 2006; 82: 853.
58. Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplantation Proc 2001; 33: 1830.
59. ANZDATA Registry Report 2004. Excell L, McDonald S, eds. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry; 2004.
60. Foley RN, Parfrey PS, Harnett J, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53.
61. Evans R, Rader B, Mansueto G. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 9: 825.
62. Powe N, Griffiths GJ, Watson A, et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 1994; 4: 1455.
63. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005; 67: 2089.
64. EBPG (European Expert Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant 2000; 15 Suppl 7: 1.
65. Revised European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004: 19(Suppl 2): ii2.
66. National Kidney Foundation. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease. Update 2000. Am J Kidney Dis 2006; 47: 5.
67. Pollock C, McMahon L. Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology (Carlton). 2005 Oct; 10 Suppl 4: S108.
68. Kasiske L, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1.
69. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJ. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004; 65(2): 692.
70. Mix T, Kazmi WH, Khan SS, et al. Anemia: A continuing problem following kidney transplantation. Am J Transplant 2003; 3: 1426.
71. Yorgin P, Scandling J, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429.
72. Vanrenterghem Y, Ponticelli C, Morales J, et al. Prevalence and management of anemia in renal transplant recipients: A European survey. Am J Transplant 2003; 3: 835.
73. Sun C, Ward H, Paul W, et al. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989; 321: 151.
74. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia. Arch Intern Med 2002; 162: 1401.
75. Djamali A, Kendziorski C, Brazy PC, Becker BN. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003; 64: 1800.
76. Korzets A, Zevin D, Chagnac A, et al. Angiotensin-Converting enzyme inhibition and anaemia in renal patients. Acta Haematol 1993; 90: 202.
77. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180.
78. Besarab A, Bolton K, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998: 584.
79. U.S. Renal Data System. Excerpts from USRDS 2005 Annual Data Report. Am J Kidney Dis 2006: 47 (Suppl 1): 12.
80. Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45: 1051.
81. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125.
82. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990: 300: 573.
83. Nangaku M. Chronic hypoxia and tubulointerstitial Injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17.
84. Becker BN, Becker YT, Leverson GE, Heisey DM. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17: 1667.
85. Chiu MY, Sprague SM, Bruce DS, et al. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998; 9: 677.
86. Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79: 629.
87. Ramsey-Goldman RR, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14: 456.
88. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: 566.
89. Grotz WH, Mundinger FA, Gugel B, et al. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation 1994; 58: 912.
90. Cruz EA, Lugon JR, Jorgetti V, et al. Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 2004; 44: 747.
91. Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67: 1218.
92. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol 2004; 24: 82.
93. Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis 2006; 13: 35.
94. Olgaard K, Sprague SM. Post-transplant bone disease. In: Olgaard K, ed. Bone and Mineral Metabolism in CKD. National Kidney Foundation; 2006: 141.
95. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1.
96. Ulinski T, Cochat P. Longitudinal growth in children following kidney transplantation: From conservative treatment to pharmacological strategies. Pediatr Nephrol 2006; 21: 903.
97. Chapman JR. Compliance: The Patient, The Doctor and the Medication? Transplantation 2004; 77: 782.
98. Fine RN, Stablein D. Long-term use of recombinant human growth hormone in pediatric allograft recipients: A report of the NAPRTCS Transplant Registry. Pediatr Nephrol 2005; 20: 404.
99. Nissel R, Brazda I, Feneberg R, et al. Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 2004; 66: 792.
100. Maxwell H, Rees L, for the British Association for Paediatric Nephrology. Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. Arch Dis Child 1998; 79: 481.
101. McKay DB, Josephson MA. Reproduction and transplantation: Report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant 2005; 1592.
102. Pezeshiki M, Taherian AA, Gharavy M, Ledger WL. Menstrual characteristics and pregnancy in women after renal transplantation. Intern J Gynecol Obstet 2004; 85: 119.
103. Davison JM, Bailey DJ. Pregnancy following renal transplantation. J Obstet Gynaecol Res 2003; 29: 227.
104. World Health Organization, Making Pregnancy Safer. Available at: www.who.int/making_pregnancy_safer/en/. Accessed March 2, 2007.
105. Le Ray C, Coulomb A, Elefant E, et al. Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 2004; 103: 1091.
106. Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate motefetil or sirolimus. World Transplant Congress 2006; A285.
107. De Celis R, Pedron-Nuevo N. Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive agents. Arch Andrology 1999; 42: 9.
108. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
109. Chugh KS, Jha V. Differences in the care of ESRD patients worldwide: Required resources and future outlook. Kidney Int 1995; 50: S7.
110. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002; 22: 417.
111. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
112. Chugh KS, Jha V, Chugh S. Economics of dialysis and renal transplantation in the developing world. Transplant Proc 1999; 31: 3275.
113. United Kingdom guidelines for living donor kidney transplantation. Available at: http://www.cambridgetransplant.org.uk/program/renal/ lrdgui.pdf. Accessed March 2, 2007.
114. Davis CL. Delmonico FL. Living-donor kidney transplantation: A review of the current practices for the live donor. J Am Soc Nephrol 2005; 16: 2098.
115. Matas AJ. Bartlett ST. Leichtman AB. Delmonico FL. Morbidity and mortality after living kidney donation, 1999-2001: Survey of United States transplant centers. Am J Transplant 2003; 3: 830.
116. Abecassis M, Adams M, Adams P, et al. Live Organ Donor Consensus Group. Consensus statement on the live organ donor. JAMA 2002; 284: 2919.
117. Kasiske BL, Ravenscraft M, Ramos EL, et al. The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1996; 7: 2288.
118. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173: S1.
119. World Health Organization. Configuring the hospital for the 21st century. Available at: http://www.who.it/document/E84697.pdf. Accessed March 2, 2007.
120. Work Health Organization. What are the best strategies for ensuring quality in hospitals? Available at: http://www.euro.who.int/document/ Hen/hospquality.pdf. Accessed March 2, 2007.
121. Centers for Disease Control and Prevention. Infection Control Guidelines. Available at: http://www.cdc.gov/ncidod/dhqp/guidelines.html. Accessed March 2, 2007.
122. Prevention of hospital-acquired infections. A practical guide. 2nd edition. Available at: http://www.who.int/csr/resources/publications/ drugresist/whocdscsreph200212.pdf. Accessed March 2, 2007.
123. Axelrod DA, Guidinger MK, Metzger RA, et al. Transplant center quality assessment using a continuously updatable, risk-adjusted technique (CUSUM). Am J Transplant 2006; 6: 313.
124. Cho YW, Cecka JM. Crossmatch tests, an analysis of UNOS data from 1991-2000. Clin Transpl 2001: 237.
125. Kasiske BL, Ramos EL, Gaston RS, et al. The evaluation of renal transplant candidates: Clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6: 1.
126. ACC/AHA Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Available at: http://www.acc.org/clinical/ guidelines/perio/update/pdf/perio_update.pdf. Accessed March 2, 2007.
127. Wolters U, Wolf T, Stutzer H, et al. Risk factors, complications, and outcome in surgery: A multivariate analysis. Eur J Surg 1997; 163: 563.
128. Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: A meta-analysis. J Am Soc Nephrol 2003; 14: 431.
129. Wolters U, Wolf T, Stutzer H, Schroder T. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996; 77: 217.
130. Sharma AK, Gupta R, Tolani SL, et al. Evaluation of socioeconomic factors in noncompliance in renal transplantation. Transplant Proc 2000; 32: 1864.
131. Grotz W, Siebig S, Olschewski M, et al. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004; 77: 1848.
132. Murphy GJ, Taha R, Windmill DC, et al. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg 2001; 88: 261.
133. Irish A. Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004; 4: 139.
134. Pedersen T, Dyrlund Pedersen B, Møller AM. Pulse oximetry for perioperative monitoring. Cochrane Database of Syst Rev 2003; 3: CD002013.
135. Chumillas S, Ponce JL, Delgado F, et al. Prevention of postoperative pulmonary complications through respiratory rehabilitation: a controlled clinical study. Arch Phys Med Rehabil 1998; 79: 5.
136. Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database of Syst Rev 2005; 4: CD004925.
137. Sprung J, Kapural L, Bourke DL, O'Hara JF Jr. Anesthesia for kidney transplant surgery. Anesthesiol Clin North America 2000; 18: 919.
138. Akpek EA, Kayhan Z, Donmez A, et al. Early postoperative renal function following renal transplantation surgery: Effect of anesthetic technique. J Anesth 2002; 16: 114.
139. Sener M, Torgay A, Akpek E, et al. Regional versus general anesthesia for donor nephrectomy: Effects on graft function. Transplant Proc 2004; 36: 2954.
140. Ahmad N, Pratt JR, Potts DJ, Lodge JP. Comparative efficacy of renal preservation solutions to limit functional impairment after warm ischemic injury. Kidney Int 2006; 69: 884.
141. Wight J, Chilcott J, Holmes M, Brewer N. The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and nonheart-beating donors. Health Technol Assess 2003; 7: 1.
142. Wight JP, Chilcott JB, Holmes MW, Brewer N. Pulsatile machine perfusion vs. cold storage of kidneys for transplantation: A rapid and systematic review. Clin Transplant 2003; 17: 293.
143. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
144. Danovitch GM. Immunosuppressive medications for renal transplantation: A multiple choice question. Kidney Int 2001; 59: 388.
145. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
146. Meier-Kriesche H-U, Li S, Gruessner RWG, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(Part 2): 1111.
147. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
148. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for Cyclosporine A in renal Transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" Study. Transplantation 2005; 79: 466.
149. Weir MR, Traver Ward M, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
150. Suwelack B, Garhardt U, Hohage H. Withdrawal of Cyclosporine or Tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
151. Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune maintenance regimen study. Transplantation 2003; 76: 364.
152. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A Meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
153. Pascual J, Quereda C, Zamora J, Hernàndez D. Steroid withdrawal in renal transplant patients on triple therpay with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
154. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3-years. Am J Transplant 2004; 4: 953.
155. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14: 1.
156. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation.NEngl J Med 2002; 346: 580.
157. Kramer BK, Zulke C, Kammerl MC, et al. European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Study Group. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003; 3: 982.
158. Webster A, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database of Syst Rev 2005; 4: CD003961.
159. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Syst Rev 2004; 1: CD003897.
160. Hamilton D,. Kidney transplantation: A history. In: Kidney Transplantation: Principles and Practice (4th ed). Morris PI, ed. London: Saunders, 1994: 1.
161. Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network-Transplant Data 1988-1995. Richmond, VA: UNOS and the Division of Trnasplantation, Bureau of Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD; 1996.
162. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003; 3(10): 1211.
163. Homedes N, Ugalde A. Multisource drug policies in Latin America. Bull WHO 2005; 83: 64.
164. Homedes N, Linares RL, Ugalde A. Health, Nutrition and Population (HNP) Discussion Paper. Generic Drug Policies in Latin America. HNP: The World Bank, March 2005.
165. Vincenti F Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
166. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of Basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
167. Kahan BD, Rajagopalan PR, Hall ML. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. The United States Simulect Renal Study Group. Transplantation 1999; 67: 276.
168. Brennan DC, for the Thymoglobulin Induction Study Group. Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: Expanded results from a prospective, randomised, multicenter trial [abst]. Am J Transplant 2003; 3: 438.
169. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78: 136.
170. Lebranchu Y, Bridoux F, Buchler M, et al. Immuno-prophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
171. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87.
172. Szczech LA, Berlin JA, Feldman HI, et al. The effect of antilymphocyte induction therapy on renal allograft survival. Ann Intern Med 1998; 128: 817.
173. Gaston RS, Hudson SL, Dierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103.
174. Shoskes DA, Halloran F. Delayed graft function in renal transplantation. Etiology, management and long-term significance. J Urol 1996; 155: 1831.
175. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression: A 5-year experience. Am J Transplant 2005; 5: 2473.
176. Woodle ES, Vincenti F, Lorber MI et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5: 157.
177. Min DI, Perry PJ, Chen HY, Hunsicker LG. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy 1998; 18: 282.
178. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: An international consensus statement. Transplantation 2002; 73: S12.
179. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97.
180. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
181. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
182. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rjection and toxicity. Am J Transplant 2006; 6: 121.
183. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 2003; 76: 969.
184. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
185. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
186. Paraskevas S, Kandaswamy R, Humar A, et al. Predicting long-term kidney graft survival: Can new trials be performed? Transplantation 2003; 75: 1256.
187. Guttmann RD, Soulillou JP, Moore LW, et al. Proposed consensus for definitions and endpoints for clinical trials of acute kidney transplant rejection. Am J Kidney Dis 1998; 31: S40.
188. Mariat C, Alamartine E, Afiani A, et al. Predicting glomerular filtration rate in kidney transplantation: Are the K/DOQI guidelines applicable? Am J Transplant 2005; 5: 2698.
189. Kaplan B, Schold J, Herwig-Ulf MK. Poor predictive value of serum creatinine for renal allograft loss. Transplantation 2003; 3: 1560.
190. Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65: 289.
191. Perico N, Gaspari F, Remuzzi G. Assessing renal function by GFR prediction equations in kidney transplantation. Am J Transplant 2005; 5: 1175.
192. Krieger NR, Becker BN, Heisey DM, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living- related, and living-unrelated grafts. Transplantation 2003; 75: 1677.
193. Nankivell BJ, Borrows RJ, Chir B, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
194. Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005; 5: 1405.
195. Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: A literature review. Transpl Int 2005; 1121.
196. Rosenberger J, Geckova AM, vanDijk JP, et al. Prevalence and characteristics of noncompliant behaviour and its risk factors in kidney transplant recipients. Transpl Int 2005: 1072.
197. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 1839.
198. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112.
199. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344: 726.
200. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A Paired Donor Kidney Analysis. Transplantation 2002; 74: 1377.
201. Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 2004; 78: 873.
202. Nankivell BJ, Borrows RJ, Fung CL, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242.
203. Bohmig GA, Regele H, Horl WH, et al. Protocol biopsies after kidney transplantation: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transpl Int 2005; 18: 131.
204. Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004; 4: 262.
205. Marcen R, Pascual J, Tenorio M, et al. Chronic kidney disease in renal transplant recipients. Transplant Proc 2005; 37: 3718.
206. Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826.
207. Poge U, Gerhardt T, Palmedo H, et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306.
208. Raju DL, Grover VK, Shoker A. Limitations of glomerular filtration rate equations in the renal transplant patient. Clin Transplant 2005; 19: 259.
209. Poggio E, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.
210. Roodnat JI, Mulder PGH, Rischen-vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438.
211. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14: 2387.
212. Boven K, Knight J, Bader F, Rossert J, Eckardt K-U, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005: 20: ii33.
213. Danesi R, Tacca MD. Hematologic toxicity of immunosuppressive treatment. Transplant Proc 2004: 36: 703.
214. McDevitt LM, Smith LD, Somerville KT, Corbett JL, Shihab FS. A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation. Am J Transplant 2005: 5: 1948.